CD22 and acute lymphoblastic leukemia: Bivalent CD19/CD22-4-1BB CAR-T cells targeting CD19 and CD22 showed a CR rate of 60% and a BM CR of 80% in 20 patients with R/R B-ALL in a phase I dose-escalation trial.